Internal medicine

Heart valve

Heart failure

Heart valve replacement

Biology

Cardiology

Intensive care medicine

Regeneration (biology)

valvular heart disease

Valve replacement

Stenosis

Heart disease

Cell biology

Medicine

Nature Reviews Cardiology

Valvular heart disease is a major cause of morbidity and mortality worldwide. Surgical valve repair or replacement has been the standard of care for patients with valvular heart disease for many decades, but transcatheter heart valve therapy has revolutionized the field in the past 15 years. However, despite the tremendous technical evolution of transcatheter heart valves, to date, the clinically available heart valve prostheses for surgical and transcatheter replacement have considerable limitations. The design of next-generation tissue-engineered heart valves (TEHVs) with repair, remodelling and regenerative capacity can address these limitations, and TEHVs could become a promising therapeutic alternative for patients with valvular disease. In this Review, we present a comprehensive overview of current clinically adopted heart valve replacement options, with a focus on transcatheter prostheses. We discuss the various concepts of heart valve tissue engineering underlying the design of next-generation TEHVs, focusing on off-the-shelf technologies. We also summarize the latest preclinical and clinical evidence for the use of these TEHVs and describe the current scientific, regulatory and clinical challenges associated with the safe and broad clinical translation of this technology. Next-generation tissue-engineered heart valves (TEHVs) are a promising therapeutic option for patients with valvular heart disease. In this Review, Emmert and colleagues discuss the current heart valve replacement options, describe the design of TEHVs and summarize the data from preclinical and clinical studies on the use of TEHVs.

Next-generation tissue-engineered heart valves with repair, remodelling and regeneration capacity